Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sorrento Therapeutics, Inc.

https://sorrentotherapeutics.com/

Latest From Sorrento Therapeutics, Inc.

China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut

Akeso’s PD-1/CTLA-4-targeting therapy cadonilimab has been the front-runner in the bispecific antibody field in China, leading about 50 other similar agents under development by domestic pharma firms. With a new conditional approval, it has also gained a head start over home-grown PD-1/L1 antibody rivals in the cervical cancer space.

China Approvals

Too Crowded? ImmuneOncia Looks To Niches To Challenge PD-L1 Space

ImmuneOncia CEO talks to Scrip about the development strategy for its anti-PD-L1 and anti-CD47 pipeline assets as well as the advantages of having Yuhan and Sorrento as its largest shareholders.

South Korea ImmunoOncology

Appetite For Korean Biotechs Turns Sour, Voronoi Withdraws IPO

Weak broader stock market sentiment, topped with negative biotech industry news, weighs on Korean bioventure IPOs in the first quarter, with unicorn Voronoi withdrawing its IPO plan. But VC financing in the sector remains steady.

South Korea Financing

Finance Watch: Public Markets Open Back Up For Biopharma Offerings

Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains. 

Financing Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Saliva-based Testing
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • ADNAB, Inc.
    • Levena (Suzhou) Biopharma Co., Ltd
    • SCILEX Pharmaceuticals, Inc.
    • Scilex Holding Company
    • Scintilla Pharmaceuticals, Inc.
    • Semnur Pharmaceuticals, Inc.
    • Sherrington Pharmaceuticals
    • SmartPharm Therapeutics, Inc.
    • TNK Therapeutics, Inc.
    • Virttu Biologics Limited
UsernamePublicRestriction

Register